Chongqing Lummy Pharmaceutical (300006) - Total Assets

Latest as of September 2025: CN¥2.76 Billion CNY ≈ $404.21 Million USD

Based on the latest financial reports, Chongqing Lummy Pharmaceutical (300006) holds total assets worth CN¥2.76 Billion CNY (≈ $404.21 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how well can Chongqing Lummy Pharmaceutical service its debt to assess how comfortably operating cash covers total debt obligations.

Chongqing Lummy Pharmaceutical - Total Assets Trend (2006–2024)

This chart illustrates how Chongqing Lummy Pharmaceutical's total assets have evolved over time, based on quarterly financial data. See shareholders equity of Chongqing Lummy Pharmaceutical for net asset value and shareholders' equity analysis.

Chongqing Lummy Pharmaceutical - Asset Composition Analysis

Current Asset Composition (December 2024)

Chongqing Lummy Pharmaceutical's total assets of CN¥2.76 Billion consist of 62.0% current assets and 38.0% non-current assets.

Asset Category Amount (CNY) % of Total Assets
Cash & Equivalents CN¥0.00 37.5%
Accounts Receivable CN¥453.42 Million 15.9%
Inventory CN¥201.70 Million 7.1%
Property, Plant & Equipment CN¥0.00 0.0%
Intangible Assets CN¥217.27 Million 7.6%
Goodwill CN¥44.95 Million 1.6%

Asset Composition Trend (2006–2024)

This chart illustrates how Chongqing Lummy Pharmaceutical's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Chongqing Lummy Pharmaceutical market cap and net worth.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Chongqing Lummy Pharmaceutical's current assets represent 62.0% of total assets in 2024, a decrease from 64.5% in 2006.
  • Cash Position: Cash and equivalents constituted 37.5% of total assets in 2024, up from 6.0% in 2006.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, unchanged from 8.0% in 2006.
  • Asset Diversification: The largest asset category is accounts receivable at 15.9% of total assets.

Chongqing Lummy Pharmaceutical Competitors by Total Assets

Key competitors of Chongqing Lummy Pharmaceutical based on total assets are shown below.

Company Country Total Assets
Biogen Inc
NASDAQ:BIIB
USA $29.44 Billion
Pfizer Inc
SA:PFIZ34
Brazil R$207.62 Billion
AstraZeneca PLC
NYSE:AZN
USA $114.02 Billion
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SHG:600436
China CN¥18.38 Billion
Aurora Optoelectronics Co Ltd
SHG:600666
China CN¥2.22 Billion
NanJing Pharmaceutical Co Ltd
SHG:600713
China CN¥34.05 Billion
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
Brazil R$3.66 Billion
Firebrick Pharma Ltd
AU:FRE
Australia AU$2.28 Million

Chongqing Lummy Pharmaceutical - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 2.04 2.35 1.00
Quick Ratio 1.83 2.11 0.82
Cash Ratio 0.00 0.00 0.00
Working Capital CN¥852.78 Million CN¥1.06 Billion CN¥-4.58 Million

Chongqing Lummy Pharmaceutical - Advanced Valuation Insights

This section examines the relationship between Chongqing Lummy Pharmaceutical's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 2.93
Latest Market Cap to Assets Ratio 0.27
Asset Growth Rate (YoY) -1.2%
Total Assets CN¥2.86 Billion
Market Capitalization $763.29 Million USD

Valuation Analysis

Below Book Valuation: The market values Chongqing Lummy Pharmaceutical's assets below their book value (0.27x), which may indicate investor concerns about asset quality or future growth.

Slight Asset Contraction: Chongqing Lummy Pharmaceutical's assets decreased by 1.2% over the past year, which may reflect streamlining or optimization of resources.

Annual Total Assets for Chongqing Lummy Pharmaceutical (2006–2024)

The table below shows the annual total assets of Chongqing Lummy Pharmaceutical from 2006 to 2024.

Year Total Assets Change
2024-12-31 CN¥2.86 Billion
≈ $417.89 Million
-1.21%
2023-12-31 CN¥2.89 Billion
≈ $423.03 Million
-5.37%
2022-12-31 CN¥3.05 Billion
≈ $447.04 Million
+4.38%
2021-12-31 CN¥2.93 Billion
≈ $428.28 Million
-7.02%
2020-12-31 CN¥3.15 Billion
≈ $460.62 Million
-10.10%
2019-12-31 CN¥3.50 Billion
≈ $512.37 Million
+11.48%
2018-12-31 CN¥3.14 Billion
≈ $459.59 Million
+14.61%
2017-12-31 CN¥2.74 Billion
≈ $401.00 Million
+10.32%
2016-12-31 CN¥2.48 Billion
≈ $363.50 Million
-19.94%
2015-12-31 CN¥3.10 Billion
≈ $454.03 Million
+38.28%
2014-12-31 CN¥2.24 Billion
≈ $328.35 Million
+2.83%
2013-12-31 CN¥2.18 Billion
≈ $319.31 Million
+53.27%
2012-12-31 CN¥1.42 Billion
≈ $208.34 Million
+31.71%
2011-12-31 CN¥1.08 Billion
≈ $158.18 Million
+22.28%
2010-12-31 CN¥884.01 Million
≈ $129.36 Million
+35.25%
2009-12-31 CN¥653.63 Million
≈ $95.65 Million
+143.38%
2008-12-31 CN¥268.56 Million
≈ $39.30 Million
+25.09%
2007-12-31 CN¥214.69 Million
≈ $31.42 Million
+71.61%
2006-12-31 CN¥125.10 Million
≈ $18.31 Million
--

About Chongqing Lummy Pharmaceutical

SHE:300006 China Drug Manufacturers - General
Market Cap
$763.29 Million
CN¥5.22 Billion CNY
Market Cap Rank
#9983 Global
#2579 in China
Share Price
CN¥4.94
Change (1 day)
+1.44%
52-Week Range
CN¥4.25 - CN¥6.58
All Time High
CN¥11.34
About

Chongqing Lummy Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. It provides anti-tumor, anti-inflammatory, antibacterial, digestive, anti-virus, blood system, cardiovascular system, acid-base balance nutritional medicine, endocrine system drugs, tumor adjuvant medication, antifungal, and opioid receptor antagonists. Chon… Read more